Nogitecan
Myelodysplastic/Myeloproliferative Neoplasm
Explore 42 assets in Myelodysplastic/Myeloproliferative Neoplasm →Floatz Rating
B57/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03289910CT.gov Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia | — | Active Not Recruiting | — | — | — |
NCT00053287CT.gov Fludarabine/Carboplatin/Topotecan w/Thalidomide for Relapsed/Refractory AML, CML and MDS | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Myelodysplastic/Myeloproliferative Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nogitecan (this asset) | National Cancer Institute (NCI) | P2 | B · 57 |
| Etoposide | M.D. Anderson Cancer Center | P3 | BBB |
| Busulfanum | Jacqueline Garcia, MD | P2/3 | BBB |
| Cyclosporin A | Memorial Sloan Kettering Cancer Center | P3 | BBB |
| Cytarabine | Fred Hutchinson Cancer Center | P3 | BBB |
| Melphalan | M.D. Anderson Cancer Center | P2/3 | BBB |
| Fludarabine | Fred Hutchinson Cancer Center | P3 | BBB |
| Anti-Human T-Lymphocyte Immunoglobulin, Rabbit | M.D. Anderson Cancer Center | P2/3 | BBB |
| Tacrolimus | M.D. Anderson Cancer Center | P2 | BBB |
+42 more in the Myelodysplastic/Myeloproliferative Neoplasm cohort
Other indications for Nogitecan
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Primary Peritoneal Carcinoma | — | P3 | BBB · 74 |
| Cancer Of Unknown Primary Site | — | P2 | BBB · 72 |
| Non-Small Cell Lung Carcinoma | — | P3 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nogitecan in Myelodysplastic/Myeloproliferative Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/nogitecan-myelodysplasticmyeloproliferative-neoplasm-28115
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →